{"filings":[{"id":2114600,"accession_number":"0001793229-26-000065","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-08-07T10:00:26+00:00","items":["2.02","9.01"],"status":"ready","headline":"Claritev Q2 revenue up 6.6% to $257.5M; raises FY2026 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $257.5M, +6.6% YoY; net loss narrowed to $59.2M from $62.6M.","Adjusted EBITDA $155.8M, +1.1% YoY; margin 60.5% vs 63.8% in Q2 2025.","Operating cash flow $92.7M, FCF $54.6M, up from $61.2M and $36.6M a year ago.","FY2026 guidance raised: revenue to $1.00-1.02B (was $985M-1B), adj EBITDA to $610-620M.","H1 bookings over $70M; targeting $100M full-year, representing ~50% growth over 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1471636,"accession_number":"0001793229-26-000061","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-07-06T20:11:32+00:00","items":["8.01"],"status":"ready","headline":"Claritev announces death of board member John Prince","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Prince, a board member since June 2023, died; company notified on July 6, 2026.","Prince served on the Audit Committee at the time of his death.","No replacement has been announced; board size and committee composition may change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1194598,"accession_number":"0001793229-26-000056","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-06-22T20:01:26+00:00","items":["7.01"],"status":"ready","headline":"Claritev DOJ criminal investigation closed; civil probe ongoing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DOJ notified Claritev on June 17, 2026, that the antitrust grand jury proceeding is closed and the company is not under criminal investigation.","Claritev received a civil investigative demand from the DOJ Antitrust Division on May 19, 2026, and is cooperating fully.","The original confidential grand jury subpoena was received in August 2024 regarding health insurance antitrust matters.","Company states its solutions and data platform comply with antitrust laws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":489156,"accession_number":"0001793229-26-000052","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-05-18T16:00:30+00:00","items":["7.01"],"status":"ready","headline":"Claritev confirms DOJ criminal antitrust probe, received grand jury subpoena in Aug 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["DOJ Antitrust Division issued confidential grand jury subpoena in August 2024 regarding health insurance investigation.","Company states it has fully cooperated and has not been informed it is a target of the investigation.","Response follows May 14, 2026 article alleging criminal antitrust probe into Claritev.","Company reaffirms commitment to transparency and affordability in healthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95501,"accession_number":"0001793229-26-000041","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Claritev Q1 revenue $244.7M (+5.8% YoY), net loss widens to $73.6M; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $244.7M (+5.8% YoY); Adjusted EBITDA $146.9M (+3.4%), margin 60.0%.","Net loss widened to $73.6M from $71.3M; Free Cash Flow negative $(92.5)M.","Cash balance $21.3M at March 31, 2026, down from prior quarter.","Updated FY2026 revenue guidance narrowed to $985M-$1B; EBITDA, capex, FCF guidance unchanged.","Bookings strength in core offerings and provider/government verticals noted by management."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":244678000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95500,"accession_number":"0001793229-26-000034","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Claritev shareholders approve 2.375M share increase to equity plan; all proposals pass","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved plan amendment increasing share reserve by 2.375M shares to total 7,771,250 shares.","Elected four Class III directors: Colaluca, Klein, Thorpe, and White.","Ratified PwC as independent auditor for FY 2026 with 13,184,259 votes for.","Advisory say-on-pay resolution passed with 9,005,937 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108621,"accession_number":"0001793229-26-000021","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Claritev holds 2026 Investor Day; no material updates in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Claritev hosted its 2026 Investor Day on March 16, 2026 in New York.","The slide presentation furnished to the SEC does not contain specific financial results or guidance.","Investor day covered company strategy and outlook, but details are not disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108620,"accession_number":"0001793229-26-000012","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Claritev Q4 revenue $246.6M (+6.2% YoY); FY 2025 revenue $965.4M; 2026 guidance and $75M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $246.6M (+6.2% YoY); net loss narrowed to $80.6M from $138.0M; adjusted EBITDA $151.3M.","FY 2025 revenue $965.4M (+3.7%); net loss $284.3M vs $1.6458B; adjusted EBITDA $602.6M (+4.5%).","FY 2026 guidance: revenue $980M-$1B, adj. EBITDA $605M-$615M, FCF $0M-$10M, capex $160M-$170M.","Board approved $75M share repurchase program; $20M annual limit; valid through Dec 31, 2030.","Q4 free cash flow $36.4M vs ($63.8M) YoY; year-end cash $16.8M; claims processed $47.2B in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-17.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":965413000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108619,"accession_number":"0001793229-26-000005","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Claritev presents at J.P. Morgan healthcare conference; slide deck available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide presentation furnished under Item 7.01 Regulation FD; no specific financial data disclosed in the filing.","Presenters are President & CEO Travis Dalton and CFO Doug Garis.","No earnings, guidance, or operational metrics included in the submitted exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125074,"accession_number":"0001793229-25-000172","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Claritev director Dale White ends strategic advisor role, remains on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dale White's strategic advisor role terminates effective December 31, 2025.","Mr. White will continue to serve as a director on Claritev's board.","Company waived its right to 30 days' written notice of termination.","No additional compensation is due related to his strategic advisor service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125073,"accession_number":"0001104659-25-112555","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hellman & Friedman affiliates sell 1.5M shares of Claritev at $51.50 in secondary offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Affiliates of Hellman & Friedman sold 1,500,000 shares of Class A common stock at $51.50 per share.","Company did not sell any shares and received no proceeds from the offering.","Underwriters granted 30-day option to purchase up to additional 225,000 shares.","Offering closed on November 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125072,"accession_number":"0001793229-25-000168","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Claritev Q3 revenue $246M (+6.7%), adj EBITDA $155.1M, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $246M (+6.7% YoY); net loss $69.8M vs $391.5M in Q3 2024.","Adjusted EBITDA $155.1M (+9.5% YoY), margin 63.1% vs 61.5%.","FY 2025 revenue growth guidance raised to 2.8%-3.2% from flat-to-2%.","Free cash flow -$16.3M vs +$41.1M; operating cash flow $19.9M vs $72.8M.","Processed $45.9B in claim charges; identified $6.1B potential medical savings."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":718859000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125071,"accession_number":"0001793229-25-000160","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Claritev renews contracts with top 10 clients, securing 70% of FY2024 revenue","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Renewed all ten largest clients from FY2024; those clients contributed ~70% of total 2024 revenue.","Excluding auto-renewing contracts, renewed clients accounted for ~57% of FY2024 revenue.","Weighted average contract term exceeds three years, excluding one-year auto-renewing contracts.","Company reaffirms focus on affordability, transparency, quality via AI and technology platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141766,"accession_number":"0001793229-25-000156","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Claritev appoints Brock Albinson as SVP & CAO, effective Sept 29, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brock Albinson, previously ADP Corporate Controller (2015-2024), replaces Gerald Kozel as principal accounting officer.","Base salary of $375,000; target annual cash incentive of 50% of base salary.","Eligible for annual LTIP grants starting 2026 with target of 150% of base salary.","Initial RSU grant of $150,000, vesting ratably over 4 years from first anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141765,"accession_number":"0001793229-25-000151","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Claritev provides investor slide presentation; no substantive news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated September 3, 2025 made available on company website.","Filing does not contain any new financial results, guidance, or material events.","No specific numbers, names, or strategic initiatives are provided in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141764,"accession_number":"0001793229-25-000132","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Claritev reports Q2 2025 revenue up 3.5%, net loss narrows to $62.6M, raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $241.6M (+3.5% YoY); net loss of $62.6M vs $576.7M loss in Q2 2024.","Adjusted EBITDA of $154.0M (63.8% margin), up from $146.7M in Q2 2024.","Free cash flow turned positive at $36.6M vs ($7.0)M in prior year quarter.","FY2025 guidance raised: revenue now flat to +2% (from -2% to flat); FCF range improved to ($20M) to $20M.","Capex guidance raised to $170M-$180M; no change to adjusted EBITDA margin or effective tax rate."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":472900000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159665,"accession_number":"0001793229-25-000106","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Claritev Q1 revenue $231.3M (-1.4% YoY); net loss $71.3M vs $539.7M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $231.3M, down 1.4% from $234.5M; net loss improved to $71.3M from $539.7M.","Adjusted EBITDA $142.1M (61.4% margin) vs $146.8M in prior year.","Free cash flow negative $(68.9)M vs positive $19.2M; cash $23.1M.","Reaffirmed FY2025 guidance: revenue (2)% to flat, Adj. EBITDA margin 62.5%-63.5%, FCF $(65)-$(75)M.","Announced strategic alliances with Oracle, J2 Health, and Burjeel Holdings; new Chief Medical and AI officers."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":231330000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159664,"accession_number":"0001793229-25-000084","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Claritev shareholders approve amendment to 2020 incentive plan, raising share reserve by 1.75M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2020 Omnibus Incentive Plan, increasing share reserve by 1,750,000 to 5,396,250 shares (96.3% of votes cast for).","All three Class II director nominees (Clarke, Klapstein, Kap) elected with at least 95.9% of votes for.","Ratification of PricewaterhouseCoopers as independent auditor for FY2025 received 99.4% of votes.","Say-on-pay advisory vote approved with 98.9% of votes cast (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178050,"accession_number":"0001793229-25-000061","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Claritev amends CEO/CFO employment agreements, enhances severance and equity awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Travis Dalton gets 2x base salary plus target bonus severance on termination after change in control; CFO gets 1.5x.","Four other executives (Hogge, Kim, Misencik, Nutter) receive severance letters with 0.5x to 1.5x multiples.","CEO's 2025 annual equity: $2.67M time-based RSUs (4-yr vest) and $8M cash-settled RSUs (2-yr vest) with 4x cap.","Cash-settled RSUs include potential excess payment if change in control within 5 years after grant.","Enhanced vesting provisions for death, disability, termination without cause, or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178049,"accession_number":"0001793229-25-000058","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Claritev posts investor slide presentation; no financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide presentation made available on Claritev's website on March 5, 2025.","Presenters include CEO Travis Dalton, CFO Doug Garis, COO Jerry Hogge, and others.","Presentation contains only introductory slides and a disclaimer; no performance data provided.","Filing is a routine Regulation FD disclosure; no material news conveyed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178048,"accession_number":"0001793229-25-000018","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Claritev Q4 rev $232.1M (-4.9%), net loss $138M; FY net loss $1.65B; guidance rev -2% to flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $232.1M, down 4.9% YoY; net loss $138.0M vs $31.4M loss a year ago.","FY2024 revenue $930.6M, down 3.2% YoY; net loss $1,645.8M vs $91.7M; adj. EBITDA $576.7M vs $618.0M.","FY2025 guidance: revenue flat to down 2%, adj. EBITDA margin 62.5%-63.5%, free cash flow $(65)-$(75)M.","FY2024 free cash flow negative $10.5M vs positive $62.9M; operating cash flow $107.6M vs $171.7M.","Debt refinancing with 99.75% participation completed; company rebranded as Claritev from MultiPlan."],"consensus_eps_estimate":null,"consensus_eps_actual":-101.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":930624000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178047,"accession_number":"0001793229-25-000014","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Claritev launches multi-year Transformation Program targeting 10-15% OpEx efficiencies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Program focuses on digital transformation (Oracle Cloud), business realignment, and process optimization.","Estimates 10-15% net efficiencies to operating expenses (cost of services, G&A) over several years.","2025 incremental capex of $20M-$30M for Transformation Program investments.","Prior supporting actions: rebranding, debt refinancing, and strategic alliance with Oracle.","Transformation Program is part of Vision 2030 plan to modernize operations and drive growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178046,"accession_number":"0001793229-25-000009","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"MultiPlan rebrands as Claritev; ticker to change to CTEV on Feb 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from MultiPlan Corporation to Claritev Corporation effective February 17, 2025.","Class A common stock ticker symbol will change from MPLN to CTEV on NYSE, expected Feb 28, 2025.","No shareholder vote required; name change does not affect shareholder rights.","Company highlights transformation and commitment to healthcare transparency via technology and AI.","Rebrand has no impact on existing suite of offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178052,"accession_number":"0001104659-25-007656","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"MultiPlan completes $3.085B debt refinancing with new first lien notes and credit facilities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M New 6.50% cash/5% PIK Second-Out A Notes due 2030 and $763M 5.75% Second-Out B Notes due 2030.","Issued $753M New 6% cash/0.75% PIK Third-Out A Notes (MPH) and $969M Third-Out B Notes (MultiPlan) due 2031.","New credit facilities: $325M First-Out Term Loans, $1.14B Second-Out Term Loans (both due 2030), and $350M revolver due 2029.","All existing secured notes, unsecured notes, convertible notes, and term loans were exchanged; old restrictive covenants eliminated.","Existing credit facility terminated and all guarantees/collateral under it to be released shortly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178051,"accession_number":"0001793229-25-000004","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MultiPlan completes exchange offers with >99% participation, extends debt maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Over 99% participation across all four debt classes: 99.42% secured notes, 99.46% unsecured notes, 99.97% convertible notes, 99.38% term loans.","Approximately $4.3B aggregate principal tendered; settlement expected January 30, 2025.","Existing debt reduced to minimal amounts: $6M secured notes, $5.3M unsecured, $0.4M convertible, $7.9M term loans.","Proposed amendments eliminate substantially all restrictive covenants and release collateral upon settlement.","New debt includes first-out term loans and second-out notes maturing 2030/2031 with cash and PIK interest components."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194723,"accession_number":"0001793229-24-000156","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MultiPlan Executive Chair Dale White steps down; Travis Dalton named Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dale White resigned as Executive Chair and employee effective Dec 31, 2024; remains on Board as a director.","CEO Travis Dalton appointed Chair of the Board, effective immediately upon White's transition.","White receives $1.5M lump sum severance, $93,797 cash bonus for 2024, and up to 18 months COBRA.","White engaged as Strategic Advisor for $50k annual retainer; consulting term auto-renews yearly.","White continues to vest in equity compensation while serving on the Board, subject to release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194722,"accession_number":"0001104659-24-131472","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"MultiPlan enters debt restructuring with ad hoc groups, extends maturities to 2029-2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Transaction Support Agreement signed with ad hoc groups holding 72% of secured notes, 89% unsecured, 94% convertible, 60% term loans.","New $350M first-out first-lien revolver matures Dec 2029; existing revolver maturity extended from 2026.","Exchange offers for $1.05B secured, $0.98B unsecured, $1.25B convertible, $1.28B term loans into new first-lien notes and term loans.","Consent solicitations to eliminate restrictive covenants and release collateral securing secured notes.","Deal contingent on majority participation by each series of existing debt holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194721,"accession_number":"0001793229-24-000146","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan posts Q3 net loss $391.5M on $361.6M goodwill impairment; revenue down 5.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $230.5M (-5.1% YoY); net loss $391.5M vs loss $24.1M in Q3 2023.","Adjusted EBITDA $141.6M (down from $152.3M); Free Cash Flow $41.1M (down from $49.7M).","Recorded $361.6M impairment charge for goodwill and indefinite-lived intangibles.","Identified $6.4B potential medical cost savings in Q3, +10% YoY.","Updated FY2024 guidance: revenues $930-940M (previous $935-955M), Adj. EBITDA $580-590M."],"consensus_eps_estimate":null,"consensus_eps_actual":-93.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":698479000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211027,"accession_number":"0001793229-24-000136","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"MultiPlan effects 1-for-40 reverse stock split effective Sept 20, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5:00 p.m. ET Sept 20; trading on split-adjusted basis begins Sept 23.","Each share reclassified into 1/40th share; new CUSIP 62548M209, symbol stays MPLN.","Proportional adjustments to warrants, equity awards, employee stock plans, and convertible notes (6%/7% due 2027).","No fractional shares issued; stockholders receive cash for fractional entitlements.","Purpose: meet NYSE continued listing price criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211026,"accession_number":"0001628280-24-040058","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MultiPlan exploring capital structure changes, in talks with debt holders","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["MultiPlan announced on Sept 10, 2024 it is in discussions with several debt holders to restructure its capital.","The goal is to enable the company's transformation into a data- and tech-forward healthcare firm.","No specific terms, amounts, or timeline were disclosed in the filing.","The announcement contains forward-looking statements with usual risk factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211025,"accession_number":"0001628280-24-040057","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Glenn R. August resigns from MultiPlan board effective September 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn R. August notified the Board of his immediate resignation on September 6, 2024.","Resignation is not the result of any disagreement with the Company, management, or other Board members.","Mr. August was nominated as a director by Churchill Sponsor III LLC under the Investor Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211024,"accession_number":"0001628280-24-040056","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"MultiPlan stockholders approve reverse stock split; 1-for-40 split effective Sept. 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting vote: 494,468,432 for, 5,160,539 against; proposal passed.","1-for-40 reverse split effective Sept. 20, 2024 at 5:00 p.m. ET; trading on split-adjusted basis from Sept. 23.","Outstanding shares to decrease from ~658M to ~16.5M; warrants, options, convertible notes adjusted proportionally.","Split intended to raise per-share price to meet NYSE continued listing price criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211023,"accession_number":"0001793229-24-000102","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MultiPlan CFO James Head to step down; Douglas Garis named successor effective Aug 5, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Attal resigns from Board effective Aug 1, tied to leaving Hellman & Friedman; no disagreement.","CFO James Head transitions to strategic advisor; Douglas Garis appointed EVP, CFO, Treasurer effective Aug 5.","Garis receives $535k base salary, $250k sign-on bonus, 100% target bonus, and $2M total equity vesting over three years.","Head keeps 2024 base salary, prorated bonus; unvested equity vests Dec 31, 2024 if employed through year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211022,"accession_number":"0001793229-24-000100","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan Q2 revenue down 1.9%, net loss $576.7M on $553.7M goodwill impairment, cuts FY guidance sharply","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenues $233.5M (-1.9% YoY); net loss $576.7M incl. $553.7M goodwill impairment.","Adjusted EBITDA $146.7M (down from $152.7M); identified potential savings $6.2B (+9% YoY).","CFO transition: Doug Garis named incoming CFO (effective date not specified).","FY2024 guidance cut: revenue now $935M-$955M (prior $1B-$1.03B); Adj EBITDA $580M-$595M (prior $630M-$650M).","Q3 guidance: revenue $230M-$245M; Adj EBITDA $140M-$150M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":467984000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229519,"accession_number":"0001793229-24-000084","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MultiPlan EVP, General Counsel Jeffrey Doctoroff to resign effective June 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey A. Doctoroff, EVP, General Counsel and Corporate Secretary, provided notice of resignation effective on or about June 30, 2024.","Doctoroff served at MultiPlan for nearly ten years; the Company acknowledged his contributions.","No replacement has been named; no reason for resignation was disclosed beyond the notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229518,"accession_number":"0001793229-24-000075","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan Q1 revenue $234.5M (-0.9% YoY); net loss $539.7M on $519.1M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $234.5M vs $236.6M in Q1 2023, just below guided range due to $5-6M cyber incident impact.","Net loss $539.7M vs net income $0.2M; includes $519.1M goodwill and intangible impairment.","Adjusted EBITDA $146.8M, down 6.1% from $156.3M; Free Cash Flow $19.2M vs $41.1M.","FY 2024 guidance maintained: revenue $1,000-1,030M, Adj EBITDA $630-650M; Q2 revenue guided $235-250M.","Used $18.2M cash to repay $24.4M face value of debt; $10.4M share repurchases in open market."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":234508000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229517,"accession_number":"0001793229-24-000058","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 60M share increase to 2020 Omnibus Incentive Plan; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2020 Omnibus Incentive Plan approved, increasing authorized shares by 60M to 145.85M shares.","All four Class I director nominees elected: Attal, Dalton, Harris, Prince.","Ratification of PwC as auditor for FY2024 passed (451.3M for, 2.0M against).","Advisory vote on named executive officer compensation passed (419.0M for, 4.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248061,"accession_number":"0001793229-24-000048","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"MultiPlan receives NYSE deficiency notice for sub-$1.00 average stock price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Average closing price below $1.00 over 30 consecutive trading days ended March 27, 2024.","Company has six months to regain compliance; cure requires $1.00+ closing and 30-day average.","Potential cure includes reverse stock split, subject to board and stockholder approval.","Notice has no immediate impact on listing or business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248060,"accession_number":"0001793229-24-000033","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"MultiPlan appoints Jerry Hogge as EVP and COO effective March 11, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hogge receives $500k base salary, 100% annual cash incentive target, 350% equity target.","Severance: 12 months base salary and COBRA premiums if terminated without cause.","Hogge previously grew MITRE Public Sector from $650M to $900M in under three years.","He led $4.3B DHMSM contract at Leidos, doubling revenues from $300M to over $750M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248059,"accession_number":"0001793229-24-000010","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan Q4 rev $244.1M, net loss $31.4M; guides FY24 rev $1.0B-$1.03B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $244.1M (+1.3% YoY), net loss $31.4M (vs $650.1M loss), adjusted EBITDA $156.8M.","Full year 2023 revenue $961.5M (-10.9%), net loss $91.7M (vs $572.9M loss), adjusted EBITDA $618.0M.","FY 2024 guidance: revenue $1,000M-$1,030M, EBITDA $630M-$650M; Q1 2024 revenue $235M-$250M.","Identified $22.9B potential medical cost savings in 2023; acquired Benefits Science for $140.9M; repurchased $165.8M debt.","CEO Dale White to be succeeded by Travis Dalton; White highlights progress on growth plan and debt reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":961524000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248058,"accession_number":"0001104659-24-001154","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"MultiPlan names Travis Dalton as CEO effective March 1, 2024; Dale White becomes Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Travis Dalton to succeed Dale White as President and CEO on or around March 1, 2024; Dalton previously GM of Oracle Health.","Dale White to become Executive Chair, succeeding Mark Tabak; White remains an employee and receives a $1.5M severance package.","Dalton receives base salary $825,000, sign-on bonus $500,000, target bonus 125%, and equity grants valued over $13M.","Board size increased from 12 to 13 directors; Dalton appointed as Class I director until 2024 annual meeting.","White will receive executive chair base salary of $487,500 and equity grant of $750,000 in fiscal 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248057,"accession_number":"0001793229-24-000003","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NYSE to delist MultiPlan warrants (MPLN.WS) due to abnormally low price; common stock unaffected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notified MultiPlan on Jan 2, 2024, of delisting proceedings for its warrants (MPLN.WS) due to 'abnormally low' trading price levels.","Trading in warrants suspended immediately; delisting proceedings commenced under NYSE Section 802.01D.","Company does not intend to appeal the NYSE's determination.","Common stock (MPLN) continues to trade on NYSE unaffected.","Warrants exercisable at $11.50 per share for one share of Class A common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265522,"accession_number":"0001793229-23-000119","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan Q3 2023 revenue $242.8M, net loss $24.1M; FY guidance tightened","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 revenue $242.8M (-3.1% YoY); net loss $24.1M vs net income $19.7M in Q3 2022.","Adjusted EBITDA $152.3M; Free Cash Flow $49.7M, down from $88.2M prior year.","Repurchased $46.1M face value of 5.75% Senior Unsecured Notes in open market during Q3.","FY 2023 guidance updated: revenue $960-970M (from $950-980M), Adjusted EBITDA $615-625M (from $615-635M).","Identified ~$5.8B in potential medical cost savings in Q3, up 7% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":717389000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282736,"accession_number":"0001793229-23-000115","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MultiPlan stockholders elect eight directors and approve 2023 ESPP","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected: Class II (August, Clarke, Klapstein, Philbrick) and Class III (Colaluca, Klein, Thorpe, White).","2023 Employee Stock Purchase Plan approved with 451.2M votes in favor vs 0.4M against.","No broker non-votes on either proposal, indicating strong retail support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282735,"accession_number":"0001793229-23-000109","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan Q2 2023 revenue $238M (-18% YoY), net loss $36.4M, acquires BST","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue $238.0M, down 18% from $290.1M in Q2 2022; net loss $36.4M vs net income $13.5M.","Adjusted EBITDA $152.7M, down from $209.6M in prior-year quarter; Free Cash Flow negative $(24.3)M.","Acquired Benefits Science Technologies on May 8, 2023 for $141.3M cash, adding new Data & Decision Science service line.","Updated FY 2023 guidance: revenue $950M-$980M (includes BST), Adjusted EBITDA $615M-$635M.","Q2 2023 processed $43.1B in claim charges, identifying potential savings of $5.7B; repurchased $7.4M of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":474585000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302029,"accession_number":"0001793229-23-000100","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MultiPlan elects John M. Prince to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John M. Prince elected as Class I director effective June 26, 2023.","Prince appointed to Audit Committee, replacing Richard A. Clarke.","Prince fills vacancy left by William Veghte's resignation (effective Dec 31, 2023).","Prince receives standard non-employee director compensation; no related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302028,"accession_number":"0001793229-23-000078","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"MultiPlan acquires Benefits Science LLC for $160M in cash and stock; targets >$100M incremental revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $160M: $140.8M cash + 21.6M shares of MPLN common stock; BST becomes wholly owned indirect subsidiary.","BST projected 2023 standalone revenue ~$16M with breakeven profitability; MultiPlan expects >$100M incremental annual revenue within several years.","Long-term incentive plan for BST management: up to $66M target + $16.5M max over 3-5 years based on annual recurring revenue targets.","BST's platform connects with over 160 carriers, serves ~75,000 employers; adds AI/ML capabilities to MultiPlan's new Data & Decision Science service line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302027,"accession_number":"0001793229-23-000075","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MultiPlan Q1 revenue down 21% YoY to $236.6M; net income falls 99.5% to $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 revenue $236.6M (down 20.6% YoY); net income $0.2M (down 99.5% YoY).","Adjusted EBITDA $156.3M (down 30.7% YoY); free cash flow $41.1M (down from $170.4M).","Repurchased $137.8M face value of 5.75% Senior Unsecured Notes and $5.7M of common stock.","Reaffirmed FY 2023 guidance: revenue $925-975M, Adj EBITDA $600-650M; Q2 rev $220-235M.","Processed $39.7B in claim charges, identified $5.6B potential medical cost savings (up 3% QoQ)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":236594000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302026,"accession_number":"0001793229-23-000060","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MultiPlan shareholders elect directors, ratify auditor, approve executive compensation and ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Class III directors (Colaluca, Klein, Thorpe, White) each elected with >332M votes for, <76M withheld.","Ratification of PwC as independent auditor for FY2023: 421.1M for, 155.8K against, 9K abstain.","Advisory vote on named executive officer compensation passed: 402.8M for, 4.8M against, 168K abstain.","Approval of 2023 Employee Stock Purchase Plan: 407.1M for, 586K against, 135K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321729,"accession_number":"0001793229-23-000028","cik":1793229,"company_name":"Claritev Corp","ticker":"CTEV","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"MultiPlan promotes Jeff Doctoroff to EVP, General Counsel & Corporate Secretary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Promotion effective February 25, 2023; base salary set at $405,000 annually.","Target bonus increased to 70% of base salary for 2023 under senior executive plan.","Severance: 9 months salary continuation plus COBRA reimbursement up to 18 months if terminated without cause.","Equity compensation eligibility unchanged; employment remains at-will.","Offer letter executed February 28, 2023, approved by Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":408294531.7771998,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-03T23:59:59+00:00|321729"}